Brain is one of the largest and most intricate organs in the human body. It consists of 100 billion nerves that communicate with a 100 trillion synapses. It is made up of midbrain, hindbrain, and forebrain. It is responsible for movement and thought produced by the body. It has its own security system-a filtering mechanism consisting of blood vessels which allow entry of essential nutrients at the same time blocking other substances-known as the blood-brain barrier. Blood-brain barrier is a semi-permeable dynamic interface which separates the capillaries which carry blood to the brain and spinal cord tissue by blocking the passage of certain substances. It is formed by highly specialized endothelial cells. The vessels of the blood-brain barrier are made up of specialized endothelial cell which line brain capillaries from the vascular system which lack fenestration of pores and allow rapid exchange of molecules between vessels and tissues. The blood-brain barrier protects the neural tissue from harmful chemicals and maintains a stable environment. However, this barrier is so effective at blocking the entry of foreign substances that it often prevents penetration of life-saving drugs to address issues like injuries and diseases. Therefore, discovery of new methods allowing the effective delivery of drugs and bio-macromolecules to the central nervous system (CNS) is of immense importance for the treatment of neurodegenerative disorders. Neurodegeneration and neuro inflammation are major events in CNS disorders like Parkinson's disease, stroke, Alzheimer's disease, and multiple sclerosis. But still, the drugs for CNS treatment, like neurotrophic factors, including BDNF, EPO (erythropoietin), and anti-inflammatory antibodies (e.g., Enbrel and Remicade), do not cross the blood-brain barrier in effective therapeutic quantities.
Growing prevalence of neurological diseases like Parkinson’s disease, meningitis, multiple sclerosis, and encephalitis, augmenting geriatric population, rising healthcare expenditure, increasing investment in R&D for the development of new drugs and delivery devices, growing awareness about healthcare, and rising number of initiatives by various governments and affiliated associations are few key factors driving the growth of the market.
Asia Pacific Blood Brain Barrier Technologies Market size was around USD XX billion in 2018. It is expected to grow at a CAGR of XX% to reach USD XX billion by 2023.
On the other hand, intricate regulatory frameworks for the approval of drugs in most countries and inordinate approval time for drugs due to the insufficient knowledge of the brain are primary restraints for the growth of the market.
By geography the market is segmented into India, China, Korea, Japan and others. Asia is anticipated to show high growth rates in the forecast period in the market, with China and India being the fastest growing markets in Asia Pacific. The primary driving forces for the market in emerging economies are the large pool of patients, growing awareness about the disease, improving healthcare infrastructure, and increasing government funding in the region.
Key players in the market are Bristol-Myers Squibb Company, Pfizer, Inc., biOasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., NeuroVive Pharmaceutical AB, and ArmaGen.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Geography
5.1.1 Introduction
5.1.2 Asia Pacific
5.1.2.1 India
5.1.2.2 China
5.1.2.3 Korea
5.1.2.4 Japan
5.1.2.5 Others
5.1.3 Y-o-Y Growth Analysis, By Geography
5.1.4 Market Attractiveness Analysis, By Geography
5.1.5 Market Share Analysis, By Geography
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allon Therapeutics, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AngioChem Inc.
8.3 Genzyme
8.4 CeNeRx BioPharma, Inc
8.5 Bioasis Technologies Inc.
8.6 Ablynx NV
8.7 Capsulution Pharma AG
8.8 International Brain Barriers Society (IBBS)
8.9 Cephalon Inc
8.10 Cognition Pharmaceuticals LLC
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
